Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX07 + HLX10 + carboplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HLX07 + HLX10 + carboplatin + nab-paclitaxel is a four-drug combination regimen being evaluated for the treatment of advanced solid tumors, especially squamous cell carcinomas of the head and neck and non-small cell lung cancer. HLX07 is a novel, recombinant, humanized anti-EGFR monoclonal antibody and a biobetter of cetuximab; HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody. Carboplatin is a platinum-based chemotherapy drug, and nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel. HLX07 blocks EGFR signaling, inhibiting tumor proliferation; HLX10 blocks PD-1, enhancing T cell anti-tumor response; carboplatin induces DNA cross-linking and apoptosis; nab-paclitaxel disrupts microtubule function and mitosis[1][4][5][7][9][10].
- Other names
- HLX07 + HLX10 + carboplatin + nab-paclitaxel
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on HLX07 + HLX10 + carboplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX07 + HLX10 + carboplatin + nab-paclitaxel.